Pembrolizumab, Favezelimab — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

2 Recruiting

9 Completed trials

1 Sponsors

21 Countries

Phase III

Phase II

Phase I/II

Phase III: 2 Phase II/III: 1 Phase II: 3 Phase I/II: 6

Oversight events:

2 urgent safety measures across 2 trials

View oversight register →

Indications tested

Renal cell carcinoma 2 Colorectal cancer stage IV 1 Small cell lung cancer extensive stage 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 12

All trials

12 total

LIGHTBEAM-U01 Substudy 01B: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination with Investigational Ag… Not authorised

2023-507179-23-00 Phase I/II 1 country Merck Sharp & Dohme LLC
A clinical study of different treatments for kidney cancer (MK-3475-03A) Recruiting

2023-506838-68-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Phase III 21 countries Merck Sharp & Dohme LLC
A clinical study of pembrolizumab with other study treatments in people with refractory lung cancer (MK-3475-B98) Ended

2023-507687-38-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended

2022-502100-70-00 Phase II/III 13 countries Merck Sharp & Dohme LLC
A clinical study of different treatments for kidney cancer (MK-3475-03B) Ended

2023-506839-15-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
A Phase 2 Study of MK-4280A for the Treatment of Selected Solid Tumors Ended

2023-505022-34-00 Phase II 4 countries Merck Sharp & Dohme LLC
MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma Ended

2023-503615-14-00 Phase II 7 countries Merck Sharp & Dohme LLC
Clinical trial of MK-4280A for colorectal cancer that has spread after previous treatment Ended

2024-511043-25-00 Phase III 4 countries Merck Sharp & Dohme LLC
Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants with Melanoma (KEYMAK… Ended

2023-506313-21-00 Phase I/II 6 countries Merck Sharp & Dohme LLC
Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melano… Ended

2023-506314-51-00 Phase I/II 2 countries Merck Sharp & Dohme LLC
Pembrolizumab (MK-3475) and pembrolizumab in combination with other investigational agents in high risk NMIBC patients unresponsive to BCG Ended

2022-502526-41-00 Phase II 7 countries Merck Sharp & Dohme LLC

Showing 1–12 of 12 trials

← All drugs A–Z